AppGenex Diagnostics creates multiplexed proteomic and molecular diagnostic panels for tuberculosis, supporting clinicians from initial screening through treatment monitoring. Their portfolio includes a serodetection test that uses fluorescently coded microbeads to achieve high sensitivity for active TB, an MDR‑TB panel that identifies resistance to four first‑line drugs, and a treatment‑response test that tracks blood biomarkers to predict therapy success.
Funding
Funding not disclosed
Founders
Product
Problem
Accurate and timely detection of active tuberculosis, drug‑resistant strains, and treatment response remains challenging due to reliance on single‑target assays and limited laboratory capacity, especially in high‑burden regions.
Solution
AppGenex Diagnostics offers a suite of multiplexed proteomic and molecular assays that enable clinicians to screen for active TB, identify resistance to first‑line drugs, and monitor therapeutic efficacy from a single blood sample. The Multiplex TB Serodetection Test uses fluorescently coded microbeads coupled with multiple recombinant antigens to achieve consistently high sensitivity and specificity for active disease. For patients who test positive, the Multiplex MDR‑TB Panel employs a set of single‑stranded nucleic acid probes on microbeads to detect mutations conferring resistance to rifampin, isoniazid, ethambutol, and streptomycin, supporting rapid selection of appropriate antibiotics. A separate Treatment Response Panel tracks blood biomarkers correlated with treatment success, helping clinicians predict and adjust therapy. An additional TB‑Plex assay, developed with a research partner, provides high‑throughput screening of non‑human primate serum and plasma for TB antibodies, facilitating pre‑clinical studies. All assays are designed for integration into existing laboratory workflows and are currently under regulatory review in India, with broader clinical development planned.
Target Audience
Primary customers are clinical laboratories, hospitals, and public‑health programs that diagnose and manage tuberculosis, as well as research institutions conducting pre‑clinical TB studies in non‑human primates.
Features
- Fluorescently coded microbead platform that multiplexes multiple recombinant TB antigens for serodetection with high sensitivity and specificity
- Molecular MDR‑TB panel using multiple single‑stranded nucleic acid probes on microbeads to detect resistance‑conferring mutations for four first‑line drugs
- Treatment Response panel measuring a panel of blood biomarkers to predict antibiotic efficacy and guide therapy adjustments
- High‑throughput TB‑Plex immunoassay for non‑human primate serum/plasma, enabling large‑scale pre‑clinical screening
- Compatibility with standard laboratory equipment and workflows, reducing the need for specialized instrumentation
- Ongoing regulatory review in India and clinical development in additional territories to support global deployment